IP Library Patent Application 15010395
Patent Application
App. No. 15/010,395

CHROMIUM COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF DIABETIC RETINOPATHY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/010,395
Abstract

The embodiments discloses herein related chromium compositions and methods of using same for the treatment and/or prevention of diabetic retinopathy. The present application is based, in part, on the surprising discovery that the administration of chromium complexes and, in particular, the administration of chromium histidinate, improves diabetic retinopathy and symptoms thereof, reduces the levels of retina malondialdehyde and glycosylated hemoglobin, and decreases oxidative stress and lipid oxidation in the eye/retina.

Claims (26)

1 . A method for treating, preventing, or ameliorating diabetic retinopathy in a subject in need thereof, the method comprising:

identifying a subject having or at risk for developing diabetic retinopathy; and

administering a therapeutically effective amount of at least one chromium complex.

2 . The method of claim 1 , wherein administering comprises injecting at least one chromium complex into the subject.

3 . The method of claim 1 , wherein administering comprises injecting at least one chromium complex into an eye of the subject.

4 . The method of claim 1 , wherein the therapeutically effective amount of at least one chromium complex is administered orally.

5 . The method of claim 1 , wherein the at least one chromium complex consists essentially of chromium and histidine, a chromium histidinate complex, or combinations thereof.

6 . The method of claim 1 , wherein the at least one chromium complex is co-administered with a second therapeutic agent selected from the group consisting of insulin, metformin, and a chromium-insulin complex.

7 . The method of claim 5 , wherein the second therapeutic agent is administered orally.

8 . The method of claim 1 , wherein the administering a therapeutically effective amount of at least one chromium complex comprises administering a topical ophthalmic formulation.

9 . A composition for topical ophthalmic administration comprising a therapeutically effective amount of one or more chromium complexes and at least one ophthalmically acceptable excipient.

10 . A method of decreasing malondialdehyde levels in the eye of subject in need thereof, the method comprising:

identifying a subject having or at risk for developing increased malondialdehyde levels; and

administering a therapeutically effective amount of at least one chromium complex.

11 . The method of claim 10 , wherein the therapeutically effective amount of at least one chromium complex is topically administered to the eye.

12 . The method of claim 10 , wherein the therapeutically effective amount of at least one chromium complex is injected into the eye.

13 . The method of claim 10 , wherein the therapeutically effective amount of at least one chromium complex is administered orally.

14 . The method of claim 10 , wherein the at least one chromium complex consists essentially of chromium and histidine, a chromium histidinate complex, or combinations thereof.

15 . The method of claim 10 , wherein the at least one chromium complex is co-administered with a second therapeutic agent selected from the group consisting of insulin, metformin, and a chromium-insulin complex.

16 . The method of claim 15 , wherein the second therapeutic agent is administered orally.

17 . The method of claim 10 , wherein the administering a therapeutically effective amount of at least one chromium complex comprises administering a topical ophthalmic formulation.

18 . A method of improving visual acuity in a subject having diabetic retinopathy, the method comprising:

identifying a subject having diabetic retinopathy; and

administering a therapeutically effective amount of at least one chromium complex.

19 . The method of claim 18 , wherein the at least one chromium complex consists essentially of chromium and histidine, a chromium histidinate complex, or combinations thereof.

20 . The method of claim 18 , wherein the at least one chromium complex is co-administered with a second therapeutic agent selected from the group consisting of insulin, metformin, and a chromium-insulin complex.

Assignments (3)
SECURITY INTEREST Recorded Nov 9, 2021
From: NUTRITION 21, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 058060/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: JDS THERAPEUTICS, LLC
To: NUTRITION 21, LLC
Reel/Frame 056933/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2016
From: KOMOROWSKI, JAMES R.; SAHIN, KAZIM
To: JDS THERAPEUTICS, LLC.
Reel/Frame 037803/0558 →